Jennifer E. Koblinski, PhD



Associate Professor
Interim Executive Director Research Infrastructure
Director, Cancer Mouse Models Core
Scientific Director, Tissue and Data Acquisition and Analysis Core (TDAAC)
Department of Pathology
Virginia Commonwealth University Health System
Email: Jennifer.Koblinski@vcuhealth.org

Education

Graduate Education

1999 Ph.D., Cancer Biology, Wayne State University School of Medicine Detroit, MI

Professional Service

2026	Key-Opinion-Leader for Revvity regarding animal imaging systems and AI software.
2025 - 26	Member, Organizing committee, Association of Biomolecular Resource Facilities annual national meeting in Pittsburg, PA
2022 - present	Executive Board Member, Preclinical Cancer Models Consortium
2024 - present	Organized animal track sessions for the Association of Biomolecular Resource Facilities national annual meeting
2022 - present	Executive Board Member, Preclinical Cancer Models Consortium, Monthly Zoom meetings of Cancer Mouse Models directors across the nation and internationally. I organized meetings in 2024 and 2025 in Miami, FL with national and international attendance. I am a founding creator of this group.
2022 - present	Member, Organizing committee for MidAtlantic directors and staff of scientific cores Association of Biomolecular Resource Facilities (ABRF) annual meeting

Recent Invited Presentations

"State of the art cancer modeling in mice" Invited speaker, 22nd Workshop: Pathology of Mouse Models for Human Disease, St Judes, Memphis, TN, 2026

"Integrating comparative pathology and histopathology to strengthen animal model research", Chair and Moderator of the session, Association for Biomolecular Resource Facilities (ABRF) National meeting, Pittsburg, PA 2026

Welcoming talk for Association for Biomolecular Resource Facilities (ABRF) Mid-Atlantic Chapter meeting, Richmond, VA, 2025

"Creating and managing an effective animal-related core", Moderator and speaker, Association for Biomolecular Resource Facilities (ABRF) Mid-Atlantic Chapter meeting, Richmond, VA, 2025

"Spatial (multi-core pipelines and management)", Moderator and speaker, Association for Biomolecular Resource Facilities (ABRF) Mid-Atlantic Chapter meeting, Richmond, VA, 2025

"Changing landscape of core facilities", Moderator, Association for Biomolecular Resource Facilities (ABRF) Mid-Atlantic Chapter meeting, Richmond, VA, 2025

"Imaging tools for the development and monitoring of tumor models" Invited speaker, Revvity's In Vivo Imaging Webinar Series, Imaging tools for the development and monitoring of tumor models, 2025

"Advancing research with humanized mice: unlocking the potential of shared resources" Invited speaker, Premeeting workshop, 9th Annual Society of Neuroimmune Pharmacology conference, Omaha, NE, 2025

"Breakthrough Career Panel" Invited Panelist, Women in STEM (WiSTEM) Global Zoom talk, 2025

"The Core Value Proposition: Articulating the Value and Impact of Cores in a Rapidly Evolving Funding Landscape" Moderator for the session Association for Biomolecular Resource Facilities (ABRF) National meeting, Las Vegas, NV, 2025

Research Grants/Contracts

Active

National Cancer Institute, Litovchick/Koblinski (MPI), $426,938
05/07/2026 - 05/06/2028, R21- GRANT14588852
Utilizing Glycosaminoglycans as a Theragnostic Approach for Treating Platinum-Resistant Gynecological Malignancies
Role: MPI, 0.6 calendar

Children's Hospital of Richmond, Faber/Koblinski (MPI), $50,000
01/01/2026 - 06/30/2027, Children's Hospital Foundation
GPX4 inhibitor-based therapy for Ewing Sarcoma
Role: MPI, 0 Calendar months

Massey Comprehensive Cancer Center, Koblinski/Bristol/James (MPI), $100,000,
10/01/2025 - 09/30/2026, CB Innovation Pilot Award, Development of Novel Models to Study HPV-Associated Anal Intraepithelial Neoplasia
Role: MPI, 0 Calendar months

National Cancer Institute, Yazbeck (PI), $399,187
07/01/2025 - 06/30/2026, 1R21CA270930-01A1,
Modeling Marginal Zone Lymphomagenesis
Role: CoI, 0.48 calendar

National Cancer Institute, Faber (PI), $2,474,242
06/01/2024 - 05/31/2029, 5R01CA215610-06
ABT-199 based therapies to treat neuroblastoma
Role: CoI, 0.24 calendar

Department of Defense, Koblinski (PI)
$1,050,038.16, 02/01/2026 - 01/31/2027
HT94252410002, Early detection of cancer disparity and treatment resistance in TNBC
Role: PI, 2.4 calendar

Department of Defense, Bear (PI), $961,900
02/01/2024 - 01/31/20276, HT94252410002
Early detection of cancer disparity and treatment resistance in TNBC
Role: CoI, 0.96 calendar

National Cancer Institute, Faber (PI), $2,083,022
01/01/2024 - 12/31/2028, 5R01CA285692-03
MYCN drives a druggable SUMOylation program in Neuroblastoma
Role: CoI, 0.24 calendar

Department of Defense, Faber (PI), $519,403
09/01/2023 - 09/01/2026, HT94252311017
Sabasumstat as a sensitizer to radiation therapy insynovial sarcoma
Role: CoI, 0.24 calendar

National Cancer Institute, Faber (PI), $3,451,499
09/01/2023 - 08/30/2028, 3R01CA276207-03S1 Revised
MYCN drives a ferroptotic vulnerability in neuroblastoma
Role: CoI, 0.24 calendar

National Cancer Institute, Faber (PI), $2,718,770
08/01/2023 - 07/31/2028, 5R01CA272710-03
SUMOylation disruption is toxic for SS18-SSX-driven synovial sarcoma
Role: CoI, 0.24 calendar

National Cancer Institute, Harrell/Trevino (MPI), $5,112,041
07/01/2023 - 06/30/2028, 5U54CA283762-03
United for Health Equity - Living PDX Program (U4HELPP)
1.2 calendar

National Cancer Institute, Winn (PI), $13,389,690
06/01/2023 - 04/30/2028, 5P30CA016059-43

Recent Publications

Peer Reviewed Publications

Floros KV, Fairchild CK Jr, Li J, Zhang K, Roberts JL, Kurupi R, Paudel D, Xing Y, Hu B, Kraskauskiene V, Hosseini N, Shen S, Inge MM, Smith-Fry K, Li L, Sotiriou A, Dalton KM, Jose A, Abdelfadiel EI, Hill RD, Slaughter JM, Shende M, Lorenz MR, Tanaka N, Kajino T, Nelson ML, Hinojosa MR, Kehinde VA, Belvin BR, Sugiokto FG, Lai Z, Dimopoulos AC, Boikos SA, Stamatouli AM, Lewis JP, Manjili MH, Ebi H, Valerie K, Li R, Poklepovic A, **Koblinski** JE, Siggers T, Banito A, Dozmorov MG, Jones KB, Radhakrishnan SK, Faber AC. Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma. Nat Commun. (2025) Nov 5;16(1):9761. PMCID: PMC12589557.

O'Carroll S, Slator C, de Paiva REF, Newsome C, Searle B, Kk S, Whittle S, Catley TE, Scoditti S, Mnich K, Peterson EJ, Hu B, **Koblinski** JE, Samali A, McKee V, Pyne ALB, Westerlund F, Farrell NP, Kellett A. A trackable trinuclear platinum complex for breast cancer treatment. Nucleic Acids Res. (2025) Jul 8;53(13):gkaf628. PMCID: PMC12266132.

Peterson EJ, Hampton JD, Weiss RJ, Clausen TM, Beaudin ARS, Deshmukh SP, Dosmorov MG, McGee Turner JB, Basu A, Vidal-Calvo EE, Daugard M, Salanti A, **Koblinski** JE, Litovchick L, Farrell NP. Glycan Profiling Identifies Chondroitin-4-sulfate as a Biomarker for Platinum Response and Therapeutic Target in Ovarian Cancer. bioRxiv [Preprint]. 2025 Oct 7:2025.10.06.675352. PMCID: PMC12632365.

Altman, J.E., Olex, A.L. Zboril, E.K., Walker, C.J., Boyd, D.C., Myrick, R.K., Hairr, N.S., **Koblinski**, J.E., Puchalapalli, M., Hu, B., Dozmorov, M.G., Chen, X.S., Chen, Y., Pero, C.M., Lehmann, B.D., Visvader, J.E., and Harrell, J.C. Single-cell transcriptional atlas of human breast cancers and model systems. (2024) Clin Transl Med. 14:e70044. PMCID: PMC11483560.

Chougoni, K.K., Neely, V., Ding, B., Oduah, E., Lam, V., Hu, B., **Koblinski**, J., Windle, B., Deb, S.P., Deb, S., Radhakrishnan, S., Harada, H., Nieva, J., and Grossman, S. Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis. (2024) Cancer Res. Commun. 4:2685-2698. PMCID:PMC11474859.

May, L. Hu, B., Jerajani, P., Jagdessh, A., Alhawiti, O., Cai, L., Semenova, N., Guo, C., Isbell, M., Deng, X., Faber, A., Pillappa, R., Bandyopadhyay, D., Want, XY., **Koblinski**, J., Bos, P., Li, H., Martin, R., and Landry, J. A sex-bias in Trail-Bcl-XL induced apoptosis could represent a new target for women with lung cancer. (2024) Cancer Res. 84:4140-4155. PMCID: PMC11649478.

Shen, S., Radhakrishnan, S.K., Harrell, J.C., Puchalapalli,M., **Koblinski**, J.*, Clevenger, C. The human intermediate prolactin receptor I-tail contributes breast oncogenesis by targeting Ras/MAPK Pathway. (2024) Endocrinology. 165:bqae039. PMID: 38713636

Floros, K.V., Fairchild, C.K., Li, J., Zhang, K., Roberts, J.L., Kurupi, R., Hu, B., Kraskauskiene, V., Hosseini, N., Shen, S., Inge, M.M., Smith-Fry, K., Li, L., Sotiriou, A., Dalton, K.M., Jose, A., Abdelfadiel, E., Xing, Y., Hill, R.D., Slaughter, J.M., Shende, M., Lorenz, M.R., Hinojosa, M.R., Blevin, B.R., Lai, Z., Boikos, S.A., Stamatouli, A.M., Lewis, J.P., Manjili, M.H., Valerie, K., Li, R., Banito,A., Poklepovic, A., **Koblinski**, J.E., Sigger, T., Dozmorov, M.G., Jones, K.B., Radhakrishnan, S.K., and Faber, A.C. Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma. (2024) Res Sq. rs.3.rs-4362092. PMCID:PMC11177989

Wu, P.Y., Van Scoyk, M., McHale, S.A., Chou, C.F., Kamran, F., Hu, B., Kraskauskiene, V., **Koblinski**, J., Vudatha, V., Zhang, D., Trevion, J.G., Huang, Y., Ma,

S.F., North, I., Hughes-Halbert, C., Seewaldt, V.L., Chen, C.Y., and Winn, R.A. Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men. 2024 iScience 27:108858. PMCID:PMC10830871

Menon, V., Katner, S.J., Lee, D.E., Peterson, E.J., **Koblinski**, J.E., and Farrell, N.P. Antitumor active trans-platinum complexes through metabolic stability and enhanced cellular accumulation. (2024) J. Inorg. Biochem. 252:112475. PMID: 36112089.

Website

The Brushstrokes of Discovery Community Engagement Mural Project: https://www.masseycancercenter.org/brushstrokes-community-project/